Crowdonomics
WatchlistPortfolio
SARCOMATRIX

Reg CF · Common Stock · May 2024

ClosedReached targetReg CFCommon Equity
via StartEngine · last checked Oct 4, 2026View campaign
Raised
$49.2K / $1.2M max
4% of ceiling · target hit day 9
Investors
20
$2.6K avg
Post-money valuation
$14.3M
pre-money + amount raised

Raised over time

Cumulative raisedInvestors
$52K$26K$0
20100
May 1, 2024 · openedJul 23, 2024 · last reading
Target ($15K) hit — May 10, 2024, day 9Deadline Jul 29, 2024 — 6 days out

Left axis: cumulative dollars raised. Right axis: cumulative investors. Live figures via StartEngine, last checked Oct 4, 2026; investor counts may lag the platform by up to a day.

Financials disclosed in this offering

FY2022–FY2023 · hover for source
$0
−$2.1M
FY2022
$0
−$103K
FY2023
RevenueNet income
Metric
FY2022
FY2023 reviewed
Income statement
Revenue
$0
$0
Cost of goods sold
$0
$0
Net income
-$2,078,929
-$103,375
Taxes paid
$0
$0
Balance sheet
Cash
$0
$36,803
Accounts receivable
$0
$0
Total assets
$0
$36,803
Short-term debt
$0
$18,894
Long-term debt
$0
$113,330
Total liabilities
$0
$132,224
Other
Headcount
—
5

The fiscal years the issuer disclosed in this offering’s filing, as filed. Full history on the company page.

Deal terms

Pre-money$14.3M
Post-money$14.3M
Price / share$2.50
Shares offered6,000

Perks

Invest $2,000+ and receive company newsletter updates$2K+

Offering details

Target$15,000
Max$1,235,000
Min investment$500
OpenedMay 1, 2024
DeadlineJul 29, 2024
ClosedJul 29, 2024
Days active89

Links & provenance

Campaign pagePitch videoSEC filing
Source: Manual
0001665160-24-000677
Last synced Aug 18, 2026

About this data. Raised amounts and investor counts come from the platform listing and may lag or be restated; SEC-reported totals can differ until the next Form 1-Z/C-U. Post-money valuation is computed as pre-money plus amount raised and is shown once the round closes — it is not a traded price. Financial statements are as reported by the issuer. Crowdonomics is not a broker-dealer, funding portal, or investment adviser; nothing here is investment advice or an offer to sell securities. Verify all figures against the linked EDGAR filings.